Document Detail

Celecoxib is as efficacious as naproxen in the management of acute shoulder pain.
MedLine Citation:
PMID:  12760313     Owner:  NLM     Status:  MEDLINE    
This study compared the analgesic efficacy and safety of the cyclo-oxygenase-2 specific inhibitor celecoxib with the non-specific non-steroidal anti-inflammatory drug, naproxen, in patients with acute shoulder pain. Adult patients with shoulder pain, onset within the previous 14 days and shoulder pain of > or = 40 mm on a 100 mm visual analogue scale (VAS), were treated with oral doses of celecoxib or naproxen for 14 days and followed by a visit at day 42 in a double-blind, randomized study. The primary efficacy assessment was change in maximum pain at rest on a 100 mm VAS at day 14 compared with baseline. In addition, secondary efficacy pain and functional assessments were analysed at baseline, day 14 and day 42. A total of 202 patients were included in the trial (99 celecoxib 400 mg/day; 103 naproxen 1 g/day). The difference in change from baseline at day 14 in maximum pain at rest was not statistically significant between the two treatment groups, but was numerically higher for celecoxib than for naproxen (-47.9 +/- 2.5 versus -42.3 +/- 2.5, respectively). According to the limits of the 95% confidence interval of the difference between groups (-12.52; 1.38), celecoxib appeared to be at least as effective as naproxen. All secondary efficacy measures followed the same pattern, showing similarity between the two treatments with a trend in favour of celecoxib. The incidences of adverse events were similar for both groups. Fewer patients experienced epigastric pain with celecoxib (seven patients versus 14 with naproxen). This adverse event led to discontinuation in two patients receiving celecoxib and five receiving naproxen. Celecoxib 400 mg/day was at least as effective as naproxen 1 g/day in managing pain in this condition.
P Bertin; J M Béhier; E Noël; J L Leroux
Related Documents :
25217083 - Intratympanic steroids as a salvage treatment for sudden sensorineural hearing loss? a ...
8886213 - A comparison of naprelan and naprosyn in the treatment of osteoarthritis of the knee.
16487103 - Pulse itraconazole 400 mg daily in the treatment of chromoblastomycosis.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of international medical research     Volume:  31     ISSN:  0300-0605     ISO Abbreviation:  J. Int. Med. Res.     Publication Date:    2003 Mar-Apr
Date Detail:
Created Date:  2003-05-22     Completed Date:  2004-01-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0346411     Medline TA:  J Int Med Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  102-12     Citation Subset:  IM    
Department of Rheumatology, Dupuytren Hospital, Limoges, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Anti-Inflammatory Agents, Non-Steroidal / adverse effects,  therapeutic use*
Cyclooxygenase Inhibitors / adverse effects,  therapeutic use*
Double-Blind Method
Gastrointestinal Diseases / chemically induced
Middle Aged
Naproxen / adverse effects,  therapeutic use*
Pain Measurement / methods
Reproducibility of Results
Sensitivity and Specificity
Shoulder Pain / diagnosis*,  drug therapy*
Sulfonamides / adverse effects,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Cyclooxygenase Inhibitors; 0/Pyrazoles; 0/Sulfonamides; 169590-42-5/celecoxib; 22204-53-1/Naproxen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A single ascending dose study of epigallocatechin gallate in healthy volunteers.
Next Document:  The effects of prednisolone and serum malondialdehyde levels in puppies with experimentally induced ...